Breaking News, Collaborations & Alliances

AstraZeneca, Rigel Enter RA Development Pact

AstraZeneca and Rigel Pharmaceuticals entered an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational drug for rheumatoid arthritis (RA) and additional i

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca and Rigel Pharmaceuticals entered an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel’s late-stage investigational drug for rheumatoid arthritis (RA) and additional indications. Fostamatinib disodium has recently completed a comprehensive Phase II program. AZ will make an upfront payment to Rigel of $100 million, with as much as an additional $345 million based on development, regulatory, and sales...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters